alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1–25 of 111 studies in Brain scans and imaging published 2026 (page 1 of 5) · 27,380 in the whole library · How the 0–100 score works

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Other subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

What “Brain scans and imaging” covers

Brain scans and imaging — MRI, PET and other scans: what they show, how early, and how reliably.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Longitudinal Multimodal Retinal Imaging in Cognitively Normal Apolipoprotein E4 Carriers and Noncarriers

✓ Peer-reviewed alzhub usefulness score 68 out of 100. Translational vision science & technology 2026-10-05

This study analyzed 871 eyes from 439 participants (230 APOE ε4 noncarriers and 209 carriers). 5 key findings →

Design: longitudinal study Participants: 58 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Defining patient-centered amyloid PET thresholds for the onset of tauopathy in Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2026-01

We found a consistent amyloid PET × age interaction on global tau PET increase in men (ADNI/A05: p = 0.0078/0.018), with younger men showing faster amyloid-associated tau accumulation. 5 key findings →

Participants: 301 Evidence: low

Full summary, score breakdown and related studies → Original source

Longitudinal Structural MRI-Based Deep Learning And Radiomics Features For Predicting Alzheimer\\\\\\\'s Disease Progression

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Zenodo (CERN European Organization for Nuclear Research) 2026-01-01

Alzheimer\\\'s disease (AD), the leading cause of dementia worldwide, affects more than 55 million individuals and gen-erates annual healthcare costs exceeding two trillion USD [14]. 5 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source

Serial amyloid PET demonstrates marked reduction in amyloid burden following donanemab treatment: a real-world cohort study

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Japanese journal of radiology 2026-07-27

Centiloid values significantly decreased from 52.3 ± 23.4 at baseline to - 5.6 ± 16.5 at follow-up, with a mean change of - 58.0 (p < 0.001). 5 key findings →

Participants: 12 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Longitudinal Evaluation of 18 F-MK-6240 Along the Alzheimer Disease Continuum

✓ Peer-reviewed alzhub usefulness score 54 out of 100. Journal of Nuclear Medicine 2026-04-02

Baseline 18F-MK-6240 PET showed a minimal signal in CU participants, localized signal to the medial temporal lobe in participants with MCI, and a signal spanning the inferolateral temporal lobe and extending posteriorly along the ventral cortex in participants with AD. 5 key findings →

Design: longitudinal study Participants: 27 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Decoupling Alzheimer Disease Pathologic Abnormalities at PET with Improved Clinical Relevance by Interpretable Adversarial Decomposition Learning

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Radiology 2026-04-01

Pathophysiologic-constrained ADL provided interpretable, personalized pathologic maps and an AI-derived ADAD score that more closely linked PET pathologic abnormalities with multimodal clinical measures. © RSNA, 2026 3 key findings →

Design: longitudinal study Participants: 7,457 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Tau-PET and CSF MTBR-tau243 comparisons validate increased tau aggregation in females

✓ Peer-reviewed alzhub usefulness score 52 out of 100. European Journal of Nuclear Medicine and Molecular Imaging 2026-05-27

In both cohorts, CSF MTBR-tau243 was associated with tau-PET temporal meta-ROI burden (BioFINDER-2: β = 1.1, p = < 0.0001 and Knight-ADRC: β = 0.7, p = < 0.0001), and this association did not differ by sex (BioFINDER-2 β = 0.04, p = 0.6 and Knight-ADRC: β = 0.009, p = 0.9). 3 key findings →

Design: cross-sectional Participants: 446 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The short-chain fatty acid butyrate prevents gut-brain amyloid-β pathology and neuroinflammation in an Alzheimer mouse model

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Molecular Psychiatry 2026-03-05

Collectively, these findings suggest that Aβ promotes gut symptoms through alteration of ENS connectivity and butyrate counteracts these impairments with an amelioration of neuroinflammation and memory function in AD model. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Impact of Postlabeling Delay on Arterial Spin-Labeling MRI-Based Measures of Cerebral Blood Flow in a Simultaneous PET/MRI Study of Aging

✓ Peer-reviewed alzhub usefulness score 49 out of 100. American Journal of Neuroradiology 2026-04-23

O]water PET were strongest for 1800 msec single-PLD and generally decreased with longer PLDs, except the occipital lobe, where all PLDs showed poor agreement. 5 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Multi-scale 3D CNN with imbalance-aware training for structural MRI-based six-class Alzheimer disease staging

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Computers in Biology and Medicine 2026-09-22

Alzheimer's disease staging from structural magnetic resonance imaging (MRI) is challenging when clinically adjacent stages and severe class imbalance are considered simultaneously. 2 key findings →

Design: longitudinal study Participants: 3,592 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Structural Brain Correlates With Appetite and Eating Disturbances Across the Alzheimer Disease Spectrum

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Alzheimer Disease & Associated Disorders 2026-01-01

Appetite disturbances were present in 9.4% of participants and were associated with greater neuropsychiatric burden and disease severity. 4 key findings →

Design: cross-sectional Participants: 7,223 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Feasibility and Tolerability of Performing Portable MRI for Neurological Disorders in an Outpatient Neurology Clinic: A Prospective Cohort

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Annals of Clinical and Translational Neurology 2026-01-28

These findings support the feasibility, tolerability, and high patient acceptability of pMRI. 3 key findings →

Participants: 130 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Subtracting First Principal Component May Improve 4R Tau Detectability on [ 18 F]Flortaucipir Tau PET

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Journal of Nuclear Medicine 2026-01-22

Area under the receiver operating characteristic curves differentiating PSP and controls were improved by PC1 subtraction in the frontal white matter (0.54 to 0.67; P = 0.002) and subcortical (0.69 to 0.87; P < 0.001) regions. 4 key findings →

Participants: 141 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Small-Data Deep Learning for Alzheimer-Spectrum Classification from Structural MRI: A Feasibility Study Using OASIS

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Journal of Imaging 2026-08-03

Accurate estimation of Alzheimer's disease (AD) severity from structural magnetic resonance imaging (MRI) remains difficult, as disease-associated anatomical alterations are often subtle and publicly available datasets are typically too small to support robust deep learning model training. 1 key finding →

Participants: 214 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Arterial Spin‐Labeling MRI at the Cortical‐ CSF Interface: A Novel Biomarker in Alzheimer Disease

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Annals of Clinical and Translational Neurology 2026-08-07

A total of 51 patients with AD, age (median: 73 years) and 53 cognitively normal subjects (median age: 69) were included. 5 key findings →

Participants: 51 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Longitudinal Structural MRI-Based Deep Learning And Radiomics Features For Predicting Alzheimer\\\\\\\'s Disease Progression

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Zenodo (CERN European Organization for Nuclear Research) 2026-01-01

Alzheimer\\\'s disease (AD), the leading cause of dementia worldwide, affects more than 55 million individuals and gen-erates annual healthcare costs exceeding two trillion USD [14]. 5 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed